Form 4: OnKure Therapeutics Director Receives Stock Grant
Insider Transaction (Form 4)
Liam Ratcliffe, a Director of OnKure Therapeutics, Inc., received 22,350 shares of common stock on August 7, 2026.
Summary
- Grant/award: acquired 22,350 Stock Option (right to buy) on August 7, 2026; holds 22,350 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Liam Ratcliffe — Director
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-07 | Grant/award | Stock Option (right to buy) | 22,350 | — | — | 22,350 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-07 | Grant/award (22,350 shares) |
Keywords
insider transaction, Form 4, OKUR, OnKure Therapeutics, Inc., neutral, Liam Ratcliffe
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.